My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
PROY-VEGA, B; GOMEZ-LLUCH, MT; ALANON-PARDO, MM and NOTARIO-DONGIL, C. Refractory oral aftas in treatment with adalimumab and apremilast in patient with Behçet syndrome. A case report. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.1, pp.99-100. Epub Nov 21, 2022. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x20220001000018.
Behçet's disease is a multisystemic inflammatory disorder that manifests itself in a variety of ways at the cutaneous level, especially in the form of oral thrush, very often very refractory. Treatments that are useful in the symptomatology of this pathology are not very specific and not very effective; sometimes it is necessary to resort to systemic treatments, such as biologi-cal ones: among them, anti-TNFα.
We present the case of a patient diagnosed with Behçet's disease, with severe oral aphthae, very recurrent and refractory to multiple treatments. Currently, the patient has reached clinical remission in combined treatment of adalimumab and apremilast.
Keywords : Apremilast; adalimumab; Behçet; oral thrush; refractary.